Compare · KLRA vs LLY
KLRA vs LLY
Side-by-side comparison of Kailera Therapeutics Inc. (KLRA) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KLRA and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.33T, about 799.9x KLRA ($1.67B).
- LLY has hit the wire 22 times in the past 4 weeks while KLRA has been quiet.
- LLY has more recent analyst coverage (25 ratings vs 6 for KLRA).
- Company
- Kailera Therapeutics Inc.
- Eli Lilly and Company
- Price
- $12.15-5.52%
- $1411.75-0.37%
- Market cap
- $1.67B
- $1.33T
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- News (4w)
- 0
- 22
- Recent ratings
- 6
- 25
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest KLRA
- Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting
- Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection
- Kailera Therapeutics to Participate in September Investor Conferences
- SEC Form 4 filed by Chief Technology Officer Nicholson Nur
- SEC Form 3 filed by new insider Nicholson Nur
- SEC Form SCHEDULE 13G filed by Kailera Therapeutics Inc.
- SEC Form 10-Q filed by Kailera Therapeutics Inc.
- Kailera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates
- Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer
Latest LLY
- SEC Form 10-Q filed by Eli Lilly and Company
- SEC Form 8-K filed by Eli Lilly and Company
- Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio
- Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial
- Patrik Jonsson to retire after 36 years; Ilya Yuffa named president, Lilly Global Markets
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- Lilly declares fourth-quarter 2026 dividend
- Gabelli To Host 8th Annual Healthcare Symposium
- New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
- Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026